{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.7","upperLimit":"9.6","value":"4.5"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"8.2","value":"1.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"description":"Objective response rate was defined as the percentage of subjects whose best response was Complete Response (CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Results are based on central evaluation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks","id":"OG000","title":"Regorafenib (Stivarga, BAY73-4506)"},{"description":"Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS)","reportingStatus":"POSTED","timeFrame":"From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year.","title":"Objective Response Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}